Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group

Vorinostat (SAHA) with great therapeutic potential has been approved by the FDA for the treatment of cutaneous T-cell lymphoma as the first HDACs inhibitor, but the drawbacks associated with hydroxamic acid group (poor stability, easy metabolism, weak binding ability to class IIa isozymes, and poor...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Junquan, Wang, Songsong, Liu, Xingang, Lin, Ruili, Deng, Fang, Jia, Zhong, Zhang, Chenghong, Li, Zhao, Zhu, Hongtian, Tang, Lei, Yang, Pingrong, He, Dian, Jia, Qingzhong, Zhang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174758/
https://www.ncbi.nlm.nih.gov/pubmed/32351936
http://dx.doi.org/10.3389/fchem.2020.00256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174758/
https://www.ncbi.nlm.nih.gov/pubmed/32351936
http://dx.doi.org/10.3389/fchem.2020.00256

Ejemplares similares